Abstract
Hepatic encephalopathy (HE) is a common clinical complication in patients with severe liver disease. While the pathogenesis of HE is incompletely understood, ammonia has been strongly implicated as an important etiological factor, and astrocytes appear to be the primary target of its neurotoxicity. In addition to ammonia, infection and inflammation have increasingly been implicated in the pathogenesis of HE. Nuclear factor-kappa B (NF-κB), a major signaling molecule involved in inflammation and immune responses, is activated in cultured astrocytes treated with ammonia, as well as in brains of experimental animals with HE. Such activation may be a consequence of systemic inflammatory events, or as a result of hyperammonemia-induced central nervous system inflammation. Once activated, NF-κB stimulates the transcription of genes involved in immune responses and inflammation, that produce factors which may contribute to cellular dysfunction such as astrocyte swelling and glutamate transport impairment as occurs in HE. This review summarizes the evidence for NF-κB activation in HE, the signaling pathways involved in its activation, and consequences of such activation.
Keywords: acute liver failure, astrocytes, brain edema, glutamate uptake, hepatic encephalopathy, MAPKs, oxidative stress, nuclear factor-kappa B, glutamate transport, ammonia
Current Signal Transduction Therapy
Title: Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Volume: 7 Issue: 1
Author(s): A.R. Jayakumar and M.D. Norenberg
Affiliation:
Keywords: acute liver failure, astrocytes, brain edema, glutamate uptake, hepatic encephalopathy, MAPKs, oxidative stress, nuclear factor-kappa B, glutamate transport, ammonia
Abstract: Hepatic encephalopathy (HE) is a common clinical complication in patients with severe liver disease. While the pathogenesis of HE is incompletely understood, ammonia has been strongly implicated as an important etiological factor, and astrocytes appear to be the primary target of its neurotoxicity. In addition to ammonia, infection and inflammation have increasingly been implicated in the pathogenesis of HE. Nuclear factor-kappa B (NF-κB), a major signaling molecule involved in inflammation and immune responses, is activated in cultured astrocytes treated with ammonia, as well as in brains of experimental animals with HE. Such activation may be a consequence of systemic inflammatory events, or as a result of hyperammonemia-induced central nervous system inflammation. Once activated, NF-κB stimulates the transcription of genes involved in immune responses and inflammation, that produce factors which may contribute to cellular dysfunction such as astrocyte swelling and glutamate transport impairment as occurs in HE. This review summarizes the evidence for NF-κB activation in HE, the signaling pathways involved in its activation, and consequences of such activation.
Export Options
About this article
Cite this article as:
Jayakumar A.R. and Norenberg M.D., Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278197
DOI https://dx.doi.org/10.2174/157436212799278197 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin
Recent Patents on Anti-Cancer Drug Discovery An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Nanomedical Applications of Amphiphilic Dendrimeric Micelles
Current Medicinal Chemistry Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme
Current Drug Metabolism Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design The Role of 4-Thiazolidinone Scaffold in Targeting Variable Biomarkers and Pathways Involving Cancer
Anti-Cancer Agents in Medicinal Chemistry Can Targeted Therapy be Successful without Metronomic Scheduling ?
Current Topics in Medicinal Chemistry SUBJECT INDEX TO VOLUME 1
Current Drug Safety Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy
Current Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Mutant Cell Surface Receptors as Targets for Individualized Cancer Diagnosis and Therapy
Current Cancer Drug Targets Neurosarcoidosis
Current Neuropharmacology